Quantcast

Roche touts study data as eye disease market primed for shake-up


Reuters


ZURICH, Oct 29 (Reuters) - Swiss drugmaker Roche on Monday touted data for a new drug against a blindness-causing eye disease that hits millions of older people, the latest sign this multi-billion-dollar market is primed for disruption.

Roche's experimental faricimab, a bispecific antibody, showed potential for extended durability in use against the disease neovascular age-related macular degeneration, it said in a statement.

OCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd">


ZURICH, Oct 29 (Reuters) - Swiss drugmaker Roche on Monday touted data for a new drug against a blindness-causing eye disease that hits millions of older people, the latest sign this multi-billion-dollar market is primed for disruption.

Roche's experimental faricimab, a bispecific antibody, showed potential for extended durability in use against the disease neovascular age-related macular degeneration, it said in a statement.




This article appears in: Stocks , World Markets , Economy , Technology
Referenced Symbols: ROG



More from Reuters

Subscribe






See Reuters News











Research Brokers before you trade

Want to trade FX?